Senotherapeutics in Cancer and HIV

Cellular senescence is a stress-response mechanism that contributes to homeostasis maintenance, playing a beneficial role during embryogenesis and in normal adult organisms. In contrast, chronic senescence activation may be responsible for other events such as age-related disorders, HIV and cancer d...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez-Díaz, Laura, Espinosa-Sánchez, Asunción, Blanco, José Ramón, Carnero, Amancio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/306840
Acceso en línea:http://hdl.handle.net/10261/306840
https://api.elsevier.com/content/abstract/scopus_id/85127609267
Access Level:acceso abierto
Palabra clave:Senotherapy
HIV
SASP
Cancer
Senescence
Senolytic
Senostatic
id ES_85c3d4c0cbb5a9e5cbec8a186d07ef2f
oai_identifier_str oai:digital.csic.es:10261/306840
network_acronym_str ES
network_name_str España
repository_id_str
spelling Senotherapeutics in Cancer and HIVSánchez-Díaz, LauraEspinosa-Sánchez, AsunciónBlanco, José RamónCarnero, AmancioSenotherapyHIVSASPCancerSenescenceSenolyticSenostaticCellular senescence is a stress-response mechanism that contributes to homeostasis maintenance, playing a beneficial role during embryogenesis and in normal adult organisms. In contrast, chronic senescence activation may be responsible for other events such as age-related disorders, HIV and cancer development. Cellular senescence activation can be triggered by different insults. Regardless of the inducer, there are several phenotypes generally shared among senescent cells: cell division arrest, an aberrant shape, increased size, high granularity because of increased numbers of lysosomes and vacuoles, apoptosis resistance, defective metabolism and some chromatin alterations. Senescent cells constitute an important area for research due to their contributions to the pathogenesis of different diseases such as frailty, sarcopenia and aging-related diseases, including cancer and HIV infection, which show an accelerated aging. Hence, a new pharmacological category of treatments called senotherapeutics is under development. This group includes senolytic drugs that selectively attack senescent cells and senostatic drugs that suppress SASP factor delivery, inhibiting senescent cell development. These new drugs can have positive therapeutic effects on aging-related disorders and act in cancer as antitumor drugs, avoiding the undesired effects of senescent cells such as those from SASP. Here, we review senotherapeutics and how they might affect cancer and HIV disease, two very different aging-related diseases, and review some compounds acting as senolytics in clinical trials.This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00; grant from AEI-MICIU/FEDER (RED2018-102723-T); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejeria de Salud (PI-0397-2017) andProject P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Adalucia move with Europe. Additionally, we thank the Fundacion AECC and Fundacion Eugenio Rodriguez Pascual for supporting this work. LS-D and ES-M were funded by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE). AE-S was funded by Fundacion AECC.Peer reviewedMultidisciplinary Digital Publishing InstituteMinisterio de Ciencia, Innovación y Universidades (España)Agencia Estatal de Investigación (España)European CommissionCentro de Investigación Biomédica en Red Cáncer (España)Junta de AndalucíaFundación Eugenio Rodríguez PascualFundación Científica Asociación Española Contra el CáncerConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202320232022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_dcae04bcPublisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/306840https://api.elsevier.com/content/abstract/scopus_id/85127609267reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-097455-B-I00info:eu-repo/grantAgreement/AEI//RED2018-102723-Thttps://doi.org/10.3390/cells11071222Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3068402026-05-22T06:33:51Z
dc.title.none.fl_str_mv Senotherapeutics in Cancer and HIV
title Senotherapeutics in Cancer and HIV
spellingShingle Senotherapeutics in Cancer and HIV
Sánchez-Díaz, Laura
Senotherapy
HIV
SASP
Cancer
Senescence
Senolytic
Senostatic
title_short Senotherapeutics in Cancer and HIV
title_full Senotherapeutics in Cancer and HIV
title_fullStr Senotherapeutics in Cancer and HIV
title_full_unstemmed Senotherapeutics in Cancer and HIV
title_sort Senotherapeutics in Cancer and HIV
dc.creator.none.fl_str_mv Sánchez-Díaz, Laura
Espinosa-Sánchez, Asunción
Blanco, José Ramón
Carnero, Amancio
author Sánchez-Díaz, Laura
author_facet Sánchez-Díaz, Laura
Espinosa-Sánchez, Asunción
Blanco, José Ramón
Carnero, Amancio
author_role author
author2 Espinosa-Sánchez, Asunción
Blanco, José Ramón
Carnero, Amancio
author2_role author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia, Innovación y Universidades (España)
Agencia Estatal de Investigación (España)
European Commission
Centro de Investigación Biomédica en Red Cáncer (España)
Junta de Andalucía
Fundación Eugenio Rodríguez Pascual
Fundación Científica Asociación Española Contra el Cáncer
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Senotherapy
HIV
SASP
Cancer
Senescence
Senolytic
Senostatic
topic Senotherapy
HIV
SASP
Cancer
Senescence
Senolytic
Senostatic
description Cellular senescence is a stress-response mechanism that contributes to homeostasis maintenance, playing a beneficial role during embryogenesis and in normal adult organisms. In contrast, chronic senescence activation may be responsible for other events such as age-related disorders, HIV and cancer development. Cellular senescence activation can be triggered by different insults. Regardless of the inducer, there are several phenotypes generally shared among senescent cells: cell division arrest, an aberrant shape, increased size, high granularity because of increased numbers of lysosomes and vacuoles, apoptosis resistance, defective metabolism and some chromatin alterations. Senescent cells constitute an important area for research due to their contributions to the pathogenesis of different diseases such as frailty, sarcopenia and aging-related diseases, including cancer and HIV infection, which show an accelerated aging. Hence, a new pharmacological category of treatments called senotherapeutics is under development. This group includes senolytic drugs that selectively attack senescent cells and senostatic drugs that suppress SASP factor delivery, inhibiting senescent cell development. These new drugs can have positive therapeutic effects on aging-related disorders and act in cancer as antitumor drugs, avoiding the undesired effects of senescent cells such as those from SASP. Here, we review senotherapeutics and how they might affect cancer and HIV disease, two very different aging-related diseases, and review some compounds acting as senolytics in clinical trials.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_dcae04bc
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/306840
https://api.elsevier.com/content/abstract/scopus_id/85127609267
url http://hdl.handle.net/10261/306840
https://api.elsevier.com/content/abstract/scopus_id/85127609267
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-097455-B-I00
info:eu-repo/grantAgreement/AEI//RED2018-102723-T
https://doi.org/10.3390/cells11071222
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412324249436160
score 15,811543

Similares en LA Referencia